| abstract |
This invention provides the use of a silicone-basedntransdermal therapeutic system having an area of 10 to 40ncm 2 and containing 0.1 to 3.15 mg / cm 2 of Rotigotine asnactive ingredient, for the preparation of an anti-Parkinsonnmedicament which effects an improvement, compared to anplacebo treatment, of the condition of human Parkinsonnpatients, measured according to the Unified Parkinson'snDisease Rating Scale (UPDRS) parts II and III, of 2 units ornmore following administration for a time period of at leastn7 weeks. |